Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pfizer & Merck's Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

pharmafileMay 16, 2019

Tag: Pfizer , Merck , FDA

PharmaSources Customer Service